BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15872357)

  • 1. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
    Maina T; Nock BA; Zhang H; Nikolopoulou A; Waser B; Reubi JC; Maecke HR
    J Nucl Med; 2005 May; 46(5):823-30. PubMed ID: 15872357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
    Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
    Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
    Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bombesin receptor antagonists may be preferable to agonists for tumor targeting.
    Cescato R; Maina T; Nock B; Nikolopoulou A; Charalambidis D; Piccand V; Reubi JC
    J Nucl Med; 2008 Feb; 49(2):318-26. PubMed ID: 18199616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.
    Nock BA; Nikolopoulou A; Galanis A; Cordopatis P; Waser B; Reubi JC; Maina T
    J Med Chem; 2005 Jan; 48(1):100-10. PubMed ID: 15634004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA; de Jong M; Erion JL; Bugaj JE; Srinivasan A; Bernard BF; Kwekkeboom DJ; Visser TJ; Krenning EP
    J Nucl Med; 2002 Dec; 43(12):1650-6. PubMed ID: 12468515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluation.
    Marsouvanidis PJ; Maina T; Sallegger W; Krenning EP; de Jong M; Nock BA
    J Nucl Med; 2013 Oct; 54(10):1797-803. PubMed ID: 24009275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging.
    Nock B; Nikolopoulou A; Chiotellis E; Loudos G; Maintas D; Reubi JC; Maina T
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):247-58. PubMed ID: 12552343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
    J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.
    Parry JJ; Andrews R; Rogers BE
    Breast Cancer Res Treat; 2007 Jan; 101(2):175-83. PubMed ID: 16838112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
    Okarvi SM; Jammaz IA
    Nucl Med Biol; 2012 Aug; 39(6):795-804. PubMed ID: 22381782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
    Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
    J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
    Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.
    Lin KS; Luu A; Baidoo KE; Hashemzadeh-Gargari H; Chen MK; Pili R; Pomper M; Carducci M; Wagner HN
    Bioconjug Chem; 2004; 15(6):1416-23. PubMed ID: 15546210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
    de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Krenning EP; de Jong M
    J Nucl Med; 2007 Jan; 48(1):88-93. PubMed ID: 17204703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
    Okarvi SM; Al Jammaz I
    Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer.
    Yu Z; Carlucci G; Ananias HJ; Dierckx RA; Liu S; Helfrich W; Wang F; de Jong IJ; Elsinga PH
    Amino Acids; 2013 Feb; 44(2):543-53. PubMed ID: 22833158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
    Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
    J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Zhang H; Chen J; Waldherr C; Hinni K; Waser B; Reubi JC; Maecke HR
    Cancer Res; 2004 Sep; 64(18):6707-15. PubMed ID: 15374988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
    Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.